For: | CLEO Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D’Adamo G, D’Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol 2016; 8(22): 949-956 [PMID: 27574549 DOI: 10.4254/wjh.v8.i22.949] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v8/i22/949.htm |
Number | Citing Articles |
1 |
Tea Lund Laursen, Cecilie Brøckner Siggard, Konstantin Kazankov, Thomas Damgaard Sandahl, Holger Jon Møller, Adrian Ong, Mark W. Douglas, Jacob George, Britta Tarp, Lena Hagelskjaer Kristensen, Alex Lund Laursen, Akira Hiramatsu, Takashi Nakahara, Kazuaki Chayama, Henning Grønbaek. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology 2018; 53(8): 986 doi: 10.1080/00365521.2018.1481996
|
2 |
Bruna Forte Aguiar, Guilherme Rodrigues Fernandes Campos, João Paulo Vilela Rodrigues, Nayara Nathie Marques, Bárbara Floriano Molina, Cintia Bittar, Fernanda Fernandes Souza, Ana de Lourdes Candolo Martinelli, Paula Rahal, Leonardo Régis Leira Pereira. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil. Clinics and Research in Hepatology and Gastroenterology 2020; 44(3): 329 doi: 10.1016/j.clinre.2019.07.015
|
3 |
João Paulo Vilela Rodrigues, Maurílio de Souza Cazarim, Silvana Gama Florencio Chachá, Ana de Lourdes Candolo Martinelli, Leonardo Régis Leira Pereira. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saúde Pública 2020; 36(2) doi: 10.1590/0102-311x00036619
|
4 |
Karin Hepp Schwambach, Mareni Rocha Farias, Giácomo Balbinotto Neto, Carine Raquel Blatt. Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data. Value in Health Regional Issues 2020; 23: 49 doi: 10.1016/j.vhri.2020.05.002
|
5 |
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista da Sociedade Brasileira de Medicina Tropical 2018; 51(2): 146 doi: 10.1590/0037-8682-0153-2017
|